Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03069937
Recruitment Status : Recruiting
First Posted : March 3, 2017
Last Update Posted : May 30, 2019
Sponsor:
Collaborator:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Medical University of South Carolina

Brief Summary:
The purpose of this study is to look at patient outcomes when docetaxel is started prior to ADT with degarelix.

Condition or disease Intervention/treatment Phase
Metastatic Prostatic Adenocarcinoma Drug: Docetaxel Drug: Degarelix Phase 2

Detailed Description:
This study will look at two drugs, docetaxel and degarelix, which are both FDA approved for the treatment of prostate cancer. Docetaxel is a standard chemotherapy treatment for metastatic prostate cancer. Degarelix is an androgen deprivation therapy (ADT) agent that decreases the amount of testosterone in the body, which helps to fight tumor growth. Usually, docetaxel is given after ADT. This study will look at how your cancer changes when docetaxel is started before ADT. You are being asked to participate in this study because you have metastatic prostate cancer that can be treated with docetaxel and ADT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 53 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.
Actual Study Start Date : March 1, 2017
Estimated Primary Completion Date : February 1, 2020
Estimated Study Completion Date : February 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Docetaxel + Degarelix
Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
Drug: Docetaxel
The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
Other Name: taxotere

Drug: Degarelix
Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
Other Name: Firmagon




Primary Outcome Measures :
  1. PSA response at 10 months [ Time Frame: 10 months ]
    PSA complete response is defined as PSA level less than or equal to 0.2 ng/ml for two consecutive measurements at least three weeks apart. Date of complete response will be defined as the date of first recorded value less than 0.2 ng/ml. PSA partial response is defined as a decline of PSA from trial baseline of > 50% for two consecutive measurements at least three weeks apart. Date of partial response will be defined as the date of first recorded decline of > 50% baseline. Date of partial response will be defined as the date of first recorded decline of > 50% baseline. PSA progression will be defined as > 25% increase from the PSA nadir (lowest PSA value recorded since trial enrollment) and > 2 ng/dl above the nadir. Two consecutive increases must be recorded at least three weeks apart. Date of PSA progression will be defined as the first recorded PSA value that is a > 25% increase from the PSA nadir and > 2 ng/dl above the nadir.


Secondary Outcome Measures :
  1. PSA response at 6 months [ Time Frame: 6 months ]
    PSA complete response is defined as PSA level less than or equal to 0.2 ng/ml for two consecutive measurements at least three weeks apart. Date of complete response will be defined as the date of first recorded value less than 0.2 ng/ml. PSA partial response is defined as a decline of PSA from trial baseline of > 50% for two consecutive measurements at least three weeks apart. Date of partial response will be defined as the date of first recorded decline of > 50% baseline. Date of partial response will be defined as the date of first recorded decline of > 50% baseline. PSA progression will be defined as > 25% increase from the PSA nadir (lowest PSA value recorded since trial enrollment) and > 2 ng/dl above the nadir. Two consecutive increases must be recorded at least three weeks apart. Date of PSA progression will be defined as the first recorded PSA value that is a > 25% increase from the PSA nadir and > 2 ng/dl above the nadir.

  2. Frequency of adverse events (AEs) using CTCAE v. 4 [ Time Frame: 10 months ]
    Toxicity for all evaluable patients will be defined by CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 4.0.

  3. Frequency of disease progression at 12 weeks using PSA [ Time Frame: 12 weeks ]
    PSA progression will be defined as > 25% increase from the PSA nadir (lowest PSA value recorded since trial enrollment) and > 2 ng/dl above the nadir. Two consecutive increases must be recorded at least two weeks apart. Date of PSA progression will be defined as the first recorded PSA value that is a > 25% increase from the PSA nadir and > 2 ng/dl above the nadir. PSA progression will not be established during the first 12 weeks of therapy (4 cycles of docetaxel) as defined by PCWG2 criteria. Thus subjects with no PSA decline from baseline during therapy will have date of PSA progression defined as first PSA value after 12 weeks that is a > 25% increase from the PSA nadir and > 2 ng/dl above the nadir.

  4. PSA response at 12 weeks [ Time Frame: 12 weeks ]

    PSA complete response is defined as PSA level less than or equal to 0.2 ng/ml for two consecutive measurements at least two weeks apart. Date of complete response will be defined as the date of first recorded value less than 0.2 ng/ml.

    PSA Partial Response is defined as a decline of PSA from trial baseline of > 50% for two consecutive measurements at least two weeks apart. Date of partial response will be defined as the date of first recorded decline of > 50% baseline.

    PSA progression is defined in outcome 4.


  5. Development of castration resistance after initiation with ADT [ Time Frame: 10 months ]
    This will be defined as the time from initial Degarelix injection to the time of disease progression (clinical, radiographic or PSA. Determination of castration resistant disease status will require disease progression and a measured serum testosterone level less than 50 ng/dl.

  6. Progression free survival [ Time Frame: 34 months ]
    Progression free Survival (PFS) will be defined as the duration of time from start of study treatment to time of disease progression or death, whichever comes first.

  7. Overall survival (OS) [ Time Frame: 34 months ]
    OS is defined as the time interval from trial enrollment to death due to any cause. Survival times will be censored for patients lost to follow-up or still alive at the trial's termination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA Patients eligible for study participation must meet all of the following criteria.

  1. Histological or cytological diagnosis of adenocarcinoma of the prostate.
  2. Metastatic disease identified via radiographic assessment by CT scans of the chest, abdomen, pelvis, and nuclear bone scan. MRI may be used if deemed necessary by the investigator. See Section 8.5 for more details about radiographic assessment requirements.

    More specifically, patients must have at least one of the following at time of study enrollment:

    1. Any visceral metastases identified by CT scans or MRI.
    2. Site(s) of bony metastasis identified by nuclear bone scan, MRI, and/or CT scan.
    3. Lymph node based disease not considered to be within a single radiation therapy port (e.g. at or above the aortic bifurcation.)
  3. Non-castrate testosterone level, >50 ng/dl, at study enrollment.
  4. Age greater than or equal to 18 years.
  5. ECOG performance status 0-2.
  6. Meet the following hematologic criteria within 14 days of enrollment to trial:

    1. Absolute neutrophil count > 1,500/mm3
    2. Hemoglobin > 8.0 g/dl (may be transfused)
    3. Platelet count > 100,000 mm3
  7. Have adequate end-organ function as defined by the following parameters. All lab values must be obtained within 14 days of enrollment to trial:

    1. Creatinine clearance of > 30 ml/min. Creatinine clearance should be determined by the Cockcroft-Gault formula (Appendix A)
    2. AST < 2 x institutional ULN
    3. ALT < 2 x institutional ULN
    4. Total bilirubin < institutional ULN
  8. Agree to use barrier methods of birth control during the docetaxel portion of the protocol and for at least one month after last docetaxel administration.
  9. Informed and must sign and give written informed consent in accordance with institutional and federal guidelines.

EXCLUSION CRITERIA

Patients eligible for study participation CANNOT meet any of the following criteria:

  1. CNS metastases (brain or leptomeningeal).
  2. Osseous metastases felt in the opinion of the clinician to be high-risk for impending pathologic fracture or spinal cord compression.
  3. Active cardiac disease defined as symptomatic congestive heart failure, history of NYHA Class III or IV Heart Failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, active angina pectoris, myocardial infarction or coronary intervention within 6 months of registration.
  4. Prior malignancy requiring systemic therapy within the last 5 years except for treated basal or squamous cell skin cancer. History of low-grade malignancies with limited potential to progress as determined by the primary investigator may be enrolled.
  5. Subjects must not have received any previous androgen deprivation therapy (LHRH agonist or LHRH antagonist) or cytotoxic therapy for prostate cancer in the metastatic setting.

    Exception Patients may have received no more than 30 days of anti-androgen (e.g. bicalutamide) in the metastatic setting prior to the start of study treatment.

  6. Subjects must not have had more than 36 months of hormonal therapy in combination with prostatectomy or radiation in the setting of localized disease and must not have shown any evidence of disease recurrence within 12 months after stopping hormonal therapy. Disease recurrence after hormonal therapy is defined as PSA > 0.2ng/dl after prostatectomy + hormonal therapy or PSA that is 2.0ng/dl more than the PSA nadir after radiotherapy + hormonal therapy. Previous hormonal therapy to the prostate must have stopped at least 12 months prior to enrollment.
  7. Subjects must not have been treated with prior docetaxel in the setting of metastatic prostate cancer. Subjects may have been treated with docetaxel in the setting of localized prostate cancer (likely as a trial-based neoadjuvant or adjuvant approach to prostatectomy or radiation.) Subjects treated with this approach must not have shown any evidence of disease recurrence within 12 months after stopping docetaxel. Disease recurrence after docetaxel is defined as PSA > 0.2ng/dl after prostatectomy + docetaxel or PSA that is 2.0ng/dl more than the PSA nadir after radiotherapy +docetaxel. Previous docetaxel in the setting of localized prostate cancer must have stopped at least 12 months prior to study enrollment.
  8. Palliative radiation therapy may have been received but not within the 30 days prior to study treatment.
  9. Presence of peripheral neuropathy > Grade 1.
  10. Known HIV-positive
  11. Presence of any severe or uncontrolled concurrent medical condition felt in the opinion of the investigator to increase the risk of serious toxicity from the study therapy.
  12. Prior hypersensitivity to any of the components of the study drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03069937


Contacts
Layout table for location contacts
Contact: Mike Wheeler 843-792-9321 hcc-clinical-trials@musc.edu
Contact: Todd Gourdin, MD 843-792-4271 gourith@musc.edu

Locations
Layout table for location information
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Mike Wheeler    843-792-9321    hcc-clinical-trials@musc.edu   
Sponsors and Collaborators
Medical University of South Carolina
Ferring Pharmaceuticals

Layout table for additonal information
Responsible Party: Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT03069937     History of Changes
Other Study ID Numbers: 102509
Pro00061532 ( Other Identifier: MUSC )
First Posted: March 3, 2017    Key Record Dates
Last Update Posted: May 30, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Prostatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action